Verve Therapeutics, Inc. (VERV) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
500 Technology Square
Boston, MA 02139
United States of America (the)
Phone
617 603 0070
Website
Sector
Healthcare
Industry
Biotechnology
Employees
274
First IPO Date
June 17, 2021
| Name | Title | Pay | Year Born |
| Sekar Kathiresan | Co-Founder, Chief Executive Officer & Director | 1.03M | 1973 |
| Anthony Philippakis | Co-Founder & Scientific Advisory Board Member | 7,967 | N/A |
| Burt A. Adelman | Co-Founder & Independent Chairman of the Board | 100,000 | 1952 |
| Andrew D. Ashe | President, Chief Operating Officer & General Counsel | 572,955 | 1967 |
| Allison Dorval | Chief Financial Officer & Principal Accounting Officer | 690,223 | 1976 |
| Troy Lister | Chief Scientific Officer | 758,288 | 1980 |
| Kiran Musunuru | Co-Founder | 0 | N/A |
| J. Keith Joung | Co-Founder | 0 | N/A |
| Issi Rozen | Co-Founder & Strategic Advisor | 0 | N/A |
| Yasser El-Gamal | Senior Vice President of Legal Affairs & Chief Intellectual Property Counsel | 0 | 1968 |
| Jennifer Robinson | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Joan Nickerson | Chief Administrative Officer | 0 | 1969 |
| Kaitlin Duffy | Executive Director of Human Resources | 0 | N/A |
| Barry S. Ticho | Co-Founder | 0 | 1960 |
Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver. The company is also progressing with an ANGPTL3 program, which similarly aims to permanently switch off the ANGPTL3 gene in the liver. To support its endeavors, Verve maintains several key partnerships, including a collaboration and licensing pact with Beam Therapeutics Inc., a development and option agreement with Acuitas Therapeutics, Inc., and a Cas9 gene-editing technology license from The Broad Institute and the President and Fellows of Harvard College. Incorporated in 2018 and headquartered in Cambridge, Massachusetts, the organization operated under the name Endcadia, Inc. until its rebranding to Verve Therapeutics, Inc. in January 2019.